Healthcare
Upstream Bio, Inc.(UPB)
Live Price
Offline$6.10
-4.39% today
1Y Change
-45.59%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $510.00M
- Revenue Growth
- +20.4%
- EPS Growth
- -78.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Upstream Bio, Inc. (UPB) is a Healthcare stock with a market cap of $510.00M and listed on NASDAQ. The stock last traded around $6.10 and down 45.6% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +20.4%, EPS growth of -78.5%, a dividend yield of 0.0%. What stands out right now is revenue +20.4%, EPS -78.5%, free cash flow -123.3% with operating margin -5618.8% and ROIC -47.0%. Valuation already assumes a fairly strong business story at price/sales 179.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines UPB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.4% vs +7.6% peer median
Operating Margin
Below sector median
-5618.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 13, 2026 with an EPS surprise of -1.2% and a revenue surprise of +0.6%.
The operating picture looks softer than before
Revenue is at +20.4% and EPS is at -78.5%, with operating margin around -5618.8%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | -1.2% | -6.1% | -10.1% | -31.8% |
2026 Mar 26, 2026 | -8.2% | -11.4% | -3.0% | -5.0% |
2025 Nov 5, 2025 | +19.2% | -1.3% | -1.0% | +15.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UPB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
UPB Max Drawdown
-81.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UPB and SPY.
Company Overview
Upstream Bio, Inc.
NASDAQ Global Select
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
- Leadership
- E. Rand Sutherland
- IPO Date
- Oct 11, 2024
- Employees
- 52
- Street Address
- 890 Winter Street
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 208 2466
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 179.2
- Price/Book
- 1.5
Growth
- Revenue
- +20.4%
- EPS
- -78.5%
- Free Cash Flow
- -123.3%
Profitability
- Gross Margin
- 96.9%
- Operating Margin
- -5618.8%
- Net Margin
- -5026.0%
- ROE
- -36.5%
- ROIC
- -47.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 26.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.